Sinotherapeutics Inc. (688247.SH): The cooperative product Enzalutamide tablets have been approved by the National Medical Products Administration.

18:32 13/03/2026

Xuantai Pharmaceuticals (688247.SH) announced that recently, the company's jointly developed Enzaluamines tablets has received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the Enzaluamines tablets to be listed on the market.

Sinotherapeutics Inc. (688247.SH) announced that recently, the company's jointly developed Enzalutamide tablets have received the Drug Registration Certificate issued by the National Medical Products Administration, approving the listing of Enzalutamide tablets. Enzalutamide is a type of androgen receptor inhibitor. The approved indications for this drug include: use in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC); adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis; and the treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who are asymptomatic or have mild symptoms after androgen deprivation therapy (ADT) failure and have not received chemotherapy. In addition, this product received temporary approval from the U.S. Food and Drug Administration in June 2025.

STARLITE HOLD (00403) intends to establish a joint venture with the Guangdong-Hong Kong-Macao Education and Technology Innovation Center to research and produce digital content.

C&D NEWIN (00731) issued a profit warning, expecting a net loss attributable to shareholders of approximately HK$71.5 million to HK$76.5 million for the year 2025.

UBOX ONLINE (02429) issued a profit warning, expecting a decrease of approximately 64% in net loss for the 2025 fiscal year compared to the previous year.

STARLITE HOLD (00403) intends to establish a joint venture with the Guangdong-Hong Kong-Macao Education and Technology Innovation Center to research and produce digital content.

C&D NEWIN (00731) issued a profit warning, expecting a net loss attributable to shareholders of approximately HK$71.5 million to HK$76.5 million for the year 2025.

UBOX ONLINE (02429) issued a profit warning, expecting a decrease of approximately 64% in net loss for the 2025 fiscal year compared to the previous year.